• Pressemitteilung BoxID 499835

Genentech and Pfizer Share CDx Success Insights at the 4th Molecular Diagnostics for Cancer Drug Development in Boston

(PresseBox) (London, UK, ) The final agenda has been released for the 4th Molecular Diagnostics for Cancer Drug Development meeting (Boston, June 25th - 28th 2012).

The 3 day agenda features 31 expert speakers including the key project leaders of Zelboraf (Genentech) and Xalkori (Pfizer) on overcoming the scientific and commercial hurdles of targeting a drug to a specific patient subpopulation, and how they gained regulatory approval of their companion diagnostics last year.

They join oncology and diagnostics experts representing: Clovis Oncology, MD Anderson Cancer Center, Johnson & Johnson, National Cancer Institute, Astellas Pharma, Fred Hutchinson Cancer Research Center, The Biomarkers Consortium, Novartis, Daiichi-Sankyo, FDA, ImmunoGen, Bristol-Myers Squibb, Morphotek, Eisai, Bayer, Dana-Farber Cancer Institute, AVEO Pharmaceuticals, Celgene and Merck.

Visit the event website or download the brochure to see the full speaker line up and agenda.

Diese Pressemitteilungen könnten Sie auch interessieren

Primera serie de marcapasos del mundo con envío de EGMI iniciado por evento

, Medizintechnik, BIOTRONIK

BIOTRONIK, el fabricante líder de tecnología médica cardiovascular, ha dado hoy a conocer que sus últimas series de marcapasos Epyra y Etrinsa,...

GMP-Regelwerke für Medizinprodukte, aktualisierte Neuauflage

, Medizintechnik, Maas & Peither AG

Die Gruppe der Medizinprodukte ist vielfältig. Ähnlich umfassend sind die gesetzlichen Regelungen, die zur Produktion dieser Produkte beachtet...

La prima serie di pace-maker al mondo con trasmissione di ECG intracavitari triggerati dagli eventi

, Medizintechnik, BIOTRONIK

BIOTRONIK, un produttore di tecnologia medica cardiovascolare leader sul mercato, ha oggi reso noto che le ultime serie di pace-maker Epyra e...

Disclaimer